Evidence map›Paper›PMID 33889864›Full record

ArticleFacts, views & vision in ObGyn2021

Simplified sperm testing devices: a possible tool to overcome lack of accessibility and inconsistency in male factor infertility diagnosis. An opportunity for low- and middle- income countries.

J Onofre, L Geenen, A Cox, I Van Der Auwera, F Willendrup, E Andersen, R Campo, N Dhont, W Ombelet

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Facts, views & vision in ObGyn, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06188936 (Home Semen Analysis Tests As a Screening Tool for the Initial Assessment of Patients Referred to the Fertility Clinic), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06188936 early_phase1completednot on this mapstarted 2023, after this paper: background citation

Home Semen Analysis Tests As a Screening Tool for the Initial Assessment of Patients Referred to the Fertility Clinic: Assessing the Feasibility of a Randomised Trial in the UK

TypeinterventionalSponsorUniversity of AberdeenRan2023 to 2024Enrolled200ConditionsMale InfertilityArmsExSeed®, Survey
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

J OnofreGenk Institute for Fertility Technology, Genk, Belgium.
L GeenenUniversity of Hasselt, Faculty of Medicine and Life Sciences, Diepenbeek, Belgium.
A CoxDepartment of Obstetrics, Gynaecology and Infertility, Ziekenhuis Oost Limburg, Genk, Belgium.
I Van Der AuweraDepartment of Obstetrics, Gynaecology and Infertility, Ziekenhuis Oost Limburg, Genk, Belgium.
F WillendrupExSeed Health ApS, Copenhagen, Denmark.
E AndersenExSeed Health ApS, Copenhagen, Denmark.
R CampoGenk Institute for Fertility Technology, Genk, Belgium.
N DhontGenk Institute for Fertility Technology, Genk, Belgium.
W OmbeletGenk Institute for Fertility Technology, Genk, Belgium.
Ziekenhuis Oost-Limburg · BEHasselt University · BELeuven Institute for Fertility and Embryology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundManual semen assessment (MSA) is a key component in a male's fertility assessment. Clinicians rely on it to make diagnostic and treatment decisions. When performed manually, this routine laboratory test is prone to variability due to human intervention which can lead to misdiagnosis and consequently over- or under- treatment. For standardisation, continuous training, quality control (QC) programs and pricy Computer-Assisted Sperm Analysis (CASA) systems have been proposed, yet, without resolving intra- and inter-laboratory variability. In response, promising simplified sperm testing devices, able to provide cost-effective point-of-care male infertility diagnosis are prospected as a plausible solution to resolve variability and increase access to sperm testing. MATERIALS AND

methodsA throughout literature research for semen testing, sperm analysis, smart-phone assisted semen analysis, 'at-home' semen testing, male infertility, infertility in developing countries, infertility in low- and middle-income countries (LMIC) and quantitative sperm analysis was performed. A total of 14 articles, specific to 'at-home' simplified sperm assessment, were included to treat the core subject.

resultsContinuous training and consistent QC, are sine qua none conditions to achieve accurate and comparable MSA. Compliance does not rule-out variability, nevertheless. Emerging simplified sperm assessment devices are an actual alternative to resolve the lack of standardisation and accessibility to sperm analysis. YO ® , SEEM ® , and ExSeed ® are commercially available, user-friendly smartphone-based devices which can accurately measure volume, sperm concentration (millions/ml) and total motile sperm count. More broadly, by cost-effectiveness, availability, accuracy and convenient application, these devices could effectively select patients for first-line artificial reproduction treatments such as intrauterine insemination.

conclusionsAccuracy and cost-effectiveness make smart-phone based sperm testing devices a practical and realistic solution to overcome variability in MSA. Importantly, these tools represent an actual opportunity to standardise and improve male subfertility diagnosis and treatment, especially in LMIC. However, before clinical application is possible, guidelines, further testing with special attention on accuracy in washed sperm, availability, cost-benefit and reliability are required.

Indexed as

developing countrieslow- and middle-income countriesmale infertilitysemen analysissmart-phone assisted sperm assessmentvariability

Identifiers

PMID33889864
PMCPMC8051200
OpenAlexW3146558145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.